Cervical cancer screening


This Technical Report accompanies the Clinical management guidelines for the prevention of cervical cancer, developed by Cancer Council Australia.

It outlines the guideline development process and methodology, lists the clinical questions, provides all accompanying NHMRC Statement Forms, the detailed technical docuemntation for each question and the risk of bias assessment tools used to assess the included literature as a result of a systematic review.

Contents[edit source]

Guideline Development Process[edit source]

Figure 1. Overview review process

Overview review process














Clinical question list[edit source]

NHMRC Evidence statements forms[edit source]

Systematic review, modelling and literature review reports[edit source]

Management of oncogenic HPV test results - Oncogenic HPV types not 16/18

Colposcopy - Normal colposcopic findings following LBC prediction of LSIL or HSIL

Colposcopy - Type 3 TZ (previously termed ‘unsatisfactory’) colposcopy following LBC prediction of LSIL or HSIL

Management of histologically confirmed low-grade squamous abnormalities[edit source]

Management of histologically confirmed high-grade squamous abnormalities[edit source]

Treatment of HSIL
Test of Cure after treatment for HSIL (CIN2/3)

Management of glandular abnormalities[edit source]

Investigation of cytological glandular abnormalities
Follow-up after excisional treatment for AIS

Screening in Aboriginal and Torres Strait Islander women[edit source]

Screening after total hysterectomy[edit source]

Screening in pregnancy[edit source]

Screening in women who have experienced early sexual activity or have been victims of sexual abuse[edit source]

Screening in immune-deficient women[edit source]

Screening in DES-exposed women[edit source]

Investigation of abnormal vaginal bleeding[edit source]

Cohort studies (risk factors) risk of bias assessment tool[edit source]

Back to top